{
  "citations" : [ ],
  "guideline" : {
    "@id" : "https://pharmgkb.org/guidelineAnnotation/PA166265241",
    "@context" : "https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld",
    "objCls" : "Guideline Annotation",
    "id" : "PA166265241",
    "name" : "Annotation of DPWG Guideline for clozapine and CYP1A2",
    "cancerGenome" : false,
    "crossReferences" : [ ],
    "guidelineGenes" : [ ],
    "history" : [ {
      "id" : 1451697963,
      "date" : "2022-02-28T00:00:00-08:00",
      "type" : "Create",
      "version" : 1
    }, {
      "id" : 1451704268,
      "date" : "2022-03-03T16:33:37.390-08:00",
      "description" : "Annotation current with May 2021 DPWG Guideline release",
      "type" : "Note",
      "version" : 0
    }, {
      "id" : 1451723360,
      "date" : "2022-03-18T10:09:47.049-07:00",
      "description" : "Updated text based on February 2022 release. Removed extended dosing guideline due to lack of recommendations.",
      "type" : "Update",
      "version" : 0
    }, {
      "id" : 1451732907,
      "date" : "2022-03-28T09:57:51.050-07:00",
      "description" : "Annotation current with February 2022 DPWG guideline release",
      "type" : "Note",
      "version" : 0
    } ],
    "literature" : [ ],
    "pediatric" : false,
    "recommendation" : false,
    "relatedAlleles" : [ {
      "@id" : "https://pharmgkb.org/haplotype/PA165819171",
      "@context" : "https://api.pharmgkb.org/jsonld/haplotype.jsonld",
      "objCls" : "Haplotype",
      "id" : "PA165819171",
      "symbol" : "CYP1A2*1A",
      "name" : "*1A",
      "version" : 7
    }, {
      "@id" : "https://pharmgkb.org/haplotype/PA165819172",
      "@context" : "https://api.pharmgkb.org/jsonld/haplotype.jsonld",
      "objCls" : "Haplotype",
      "id" : "PA165819172",
      "symbol" : "CYP1A2*1B",
      "name" : "*1B",
      "version" : 6
    }, {
      "@id" : "https://pharmgkb.org/haplotype/PA165819173",
      "@context" : "https://api.pharmgkb.org/jsonld/haplotype.jsonld",
      "objCls" : "Haplotype",
      "id" : "PA165819173",
      "symbol" : "CYP1A2*1C",
      "name" : "*1C",
      "version" : 7
    }, {
      "@id" : "https://pharmgkb.org/haplotype/PA165819174",
      "@context" : "https://api.pharmgkb.org/jsonld/haplotype.jsonld",
      "objCls" : "Haplotype",
      "id" : "PA165819174",
      "symbol" : "CYP1A2*1D",
      "name" : "*1D",
      "version" : 6
    }, {
      "@id" : "https://pharmgkb.org/haplotype/PA165819175",
      "@context" : "https://api.pharmgkb.org/jsonld/haplotype.jsonld",
      "objCls" : "Haplotype",
      "id" : "PA165819175",
      "symbol" : "CYP1A2*1E",
      "name" : "*1E",
      "version" : 6
    }, {
      "@id" : "https://pharmgkb.org/haplotype/PA165819176",
      "@context" : "https://api.pharmgkb.org/jsonld/haplotype.jsonld",
      "objCls" : "Haplotype",
      "id" : "PA165819176",
      "symbol" : "CYP1A2*1F",
      "name" : "*1F",
      "version" : 7
    }, {
      "@id" : "https://pharmgkb.org/haplotype/PA165819178",
      "@context" : "https://api.pharmgkb.org/jsonld/haplotype.jsonld",
      "objCls" : "Haplotype",
      "id" : "PA165819178",
      "symbol" : "CYP1A2*1J",
      "name" : "*1J",
      "version" : 6
    }, {
      "@id" : "https://pharmgkb.org/haplotype/PA165819179",
      "@context" : "https://api.pharmgkb.org/jsonld/haplotype.jsonld",
      "objCls" : "Haplotype",
      "id" : "PA165819179",
      "symbol" : "CYP1A2*1K",
      "name" : "*1K",
      "version" : 7
    }, {
      "@id" : "https://pharmgkb.org/haplotype/PA165988094",
      "@context" : "https://api.pharmgkb.org/jsonld/haplotype.jsonld",
      "objCls" : "Haplotype",
      "id" : "PA165988094",
      "symbol" : "CYP1A2*1L",
      "name" : "*1L",
      "version" : 4
    }, {
      "@id" : "https://pharmgkb.org/haplotype/PA165988103",
      "@context" : "https://api.pharmgkb.org/jsonld/haplotype.jsonld",
      "objCls" : "Haplotype",
      "id" : "PA165988103",
      "symbol" : "CYP1A2*1V",
      "name" : "*1V",
      "version" : 4
    }, {
      "@id" : "https://pharmgkb.org/haplotype/PA165988104",
      "@context" : "https://api.pharmgkb.org/jsonld/haplotype.jsonld",
      "objCls" : "Haplotype",
      "id" : "PA165988104",
      "symbol" : "CYP1A2*1W",
      "name" : "*1W",
      "version" : 4
    }, {
      "@id" : "https://pharmgkb.org/haplotype/PA165819181",
      "@context" : "https://api.pharmgkb.org/jsonld/haplotype.jsonld",
      "objCls" : "Haplotype",
      "id" : "PA165819181",
      "symbol" : "CYP1A2*3",
      "name" : "*3",
      "version" : 6
    }, {
      "@id" : "https://pharmgkb.org/haplotype/PA165819182",
      "@context" : "https://api.pharmgkb.org/jsonld/haplotype.jsonld",
      "objCls" : "Haplotype",
      "id" : "PA165819182",
      "symbol" : "CYP1A2*4",
      "name" : "*4",
      "version" : 6
    }, {
      "@id" : "https://pharmgkb.org/haplotype/PA165819183",
      "@context" : "https://api.pharmgkb.org/jsonld/haplotype.jsonld",
      "objCls" : "Haplotype",
      "id" : "PA165819183",
      "symbol" : "CYP1A2*6",
      "name" : "*6",
      "version" : 6
    }, {
      "@id" : "https://pharmgkb.org/haplotype/PA165819184",
      "@context" : "https://api.pharmgkb.org/jsonld/haplotype.jsonld",
      "objCls" : "Haplotype",
      "id" : "PA165819184",
      "symbol" : "CYP1A2*7",
      "name" : "*7",
      "version" : 6
    } ],
    "relatedChemicals" : [ {
      "@id" : "https://pharmgkb.org/chemical/PA449061",
      "@context" : "https://api.pharmgkb.org/jsonld/chemical.jsonld",
      "objCls" : "Chemical",
      "id" : "PA449061",
      "name" : "clozapine",
      "version" : 8
    } ],
    "relatedGenes" : [ {
      "@id" : "https://pharmgkb.org/gene/PA27093",
      "@context" : "https://api.pharmgkb.org/jsonld/gene.jsonld",
      "objCls" : "Gene",
      "id" : "PA27093",
      "symbol" : "CYP1A2",
      "name" : "cytochrome P450 family 1 subfamily A member 2",
      "version" : 6459
    } ],
    "source" : "DPWG",
    "summaryMarkdown" : {
      "id" : 1451697966,
      "html" : "<p>There is no gene-drug interaction between CYP1A2 and clozapine.</p>\n",
      "version" : 1
    },
    "terms" : [ ],
    "textMarkdown" : {
      "id" : 1451697962,
      "html" : "<h3 id=\"february-2022-update\">February 2022 Update</h3>\n<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) has updated their recommendations for clozapine based on CYP1A2 genotype. They now conclude there is no gene-drug interaction between any CYP1A2 alleles and clozapine. As a result, all recommendation have been removed. <a download=\"DPWG_February_2022_guidelines.pdf\" href=\"https://api.pharmgkb.org/v1/download/file/attachment/DPWG_February_2022_guidelines.pdf\">See the DPWG February 2022 update</a>.</p>\n<h3 id=\"may-2021-guideline\">May 2021 Guideline</h3>\n<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) has evaluated therapeutic dose recommendations for clozapine based on CYP1A2 genotype. They recommend adjusting clozapine dose as a function of clozapine plasma concentrations in patients with one or two copies of the CYP1A2*1C allele.</p>\n<p><em>Wording in table taken from the <a download=\"DPWG_August_2019.pdf\" href=\"https://api.pharmgkb.org/v1/download/file/attachment/DPWG_August_2019.pdf\">Dutch guidelines August 2019 update</a>.</em></p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Allele/Genotype/Phenotype</th>\n<th>Drug</th>\n<th>Description</th>\n<th>Recommendation</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>CYP1A2 NM</td>\n<td>clozapine</td>\n<td>This is NOT a gene-drug interaction</td>\n<td>N/A</td>\n</tr>\n<tr>\n<td>CYP1A2 IM</td>\n<td>clozapine</td>\n<td>This is NOT a gene-drug interaction</td>\n<td>N/A</td>\n</tr>\n<tr>\n<td>CYP1A2 PM</td>\n<td>clozapine</td>\n<td>This is NOT a gene-drug interaction</td>\n<td>N/A</td>\n</tr>\n<tr>\n<td>CYP1A2*1A/*1F</td>\n<td>clozapine</td>\n<td>This is NOT a gene-drug interaction</td>\n<td>N/A</td>\n</tr>\n<tr>\n<td>CYP1A2*1C-heterozygote</td>\n<td>clozapine</td>\n<td>The genetic polymorphism can result in a reduced metabolism of clozapine. This can result in an increase in the plasma concentration of clozapine and thereby the risk of adverse events.</td>\n<td>It is not possible to offer substantiated advice for dose reduction based on the literature.<br/>1. Adjust the dose as a function of the plasma concentration of clozapine. A therapeutic range of 200-600 ng/mL has been proposed for clozapine.</td>\n</tr>\n<tr>\n<td>CYP1A2*1C/*1C</td>\n<td>clozapine</td>\n<td>The genetic polymorphism can result in a reduced metabolism of clozapine. This can result in an increase in the plasma concentration of clozapine and thereby the risk of adverse events.</td>\n<td>It is not possible to offer substantiated advice for dose reduction based on the literature.<br/>1. Adjust the dose as a function of the plasma concentration of clozapine. A therapeutic range of 200-600 ng/mL has been proposed for clozapine.</td>\n</tr>\n</tbody>\n</table>\n<p><a rel=\"noopener noreferrer\" href=\"https://www.g-standaard.nl/risicoanalyse/B0004643.PDF\" target=\"_blank\">Read for more information about this recommendation</a>, <a rel=\"noopener noreferrer\" href=\"https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\" target=\"_blank\">Read about gene information from DPWG</a></p>\n",
      "version" : 1
    },
    "userId" : "rachel",
    "version" : 4
  }
}